Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aLoOxMBMC in Acute Myocardial Infarction
NCT02672267Phase 3Completed
- Sponsor
- Altaco-XXI
- Start
- Jul 2014
- Primary completion
- Apr 2016
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ischemia-tolerant mesenchymal stem cells in acute myocardial infarction (AMI) (2 arms), sponsored by Altaco-XXI. Primary endpoint: Major Adverse Cardiac Events at 6 months. Started Jul 2014; status: completed.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT02672267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672267.